Our lab capabilities — Functional Genomics Centre
Alongside our state-of-the-art technologies, our team of CRISPR experts have the skills and technology to make your project a success.
The CRUK-AZ Functional Genomics Centre has capabilities to run CRISPR screens from initial design and cell-line selection, Cas9 cell line generation, to bioinformatic analysis and interpretation of the screen data results.
Our unique laboratory democratises access to the latest cutting-edge research tools and expertise for the thousands of scientists and clinicians funded by CRUK.
Pooled sgRNA screening
- Assay development including transduction optimization
- Generation of Cas9 expressing cell lines
- Screening execution, genomic DNA extraction, and NGS sample preparation
Bioinformatics and data analysis
- Cloud deployed analysis pipeline for bioinformatic analysis of the screen results and data interpretation
sgRNA cloning - Individual clone and pooled library
- Custom made sgRNA library production
- Virus packaging and transduction.
Scientific Lead for CRUK and Director, CRUK Cambridge Institute
Professor Greg Hannon is internationally recognised for his contribution to small RNA biology, cancer biology and mammalian genomics. He has a long history in the discovery of cancer genes and he has developed widely used tools and strategies for manipulation of gene expression in mammalian cells and animals, including generating genome-wide shRNA libraries that are available to the cancer community.
Scientific Lead for AZ and Chief Scientist, Oncology R&D, AstraZeneca
Ultan is a clinician scientist and has a lifelong interest in understanding how cancer genomes affect response in the clinic to therapy, and more recently the use of genetic screens to identify mechanisms of drug resistance in cancer. He joined AstraZeneca in 2018 with a focus on drug resistance and identifying better ways to treat this in cancer patients. Before joining AstraZeneca he was a group leader at the Wellcome Sanger Institute, where he continues to be an Honorary Faculty. He is a Fellow of the Royal College of Physicians and continues to practice as an oncologist at Addenbrooke’s Hospital in Cambridge.
Head of Laboratory
Douglas joined AstraZeneca in 2014 following a decade of research across academia and industry. Originally studying the molecular genetics of viruses during his PhD, he soon began working across different disease areas and has, over the past 5 years, been driving forward the application of functional genomics to phenotypic drug discovery. Driven by a passion to find new therapeutics that can help improve our patients lives, he is excited to join the FGC as the Head of Laboratory and lead our scientists in building a world-leading centre of expertise in functional genomics.
Deputy Head of the Laboratory
David oversees CRUK’s operational running of the facility. David has broad experience as a cell biologist working on drug discovery projects ranging from early target identification to target validation. He has a strong interest in applying and improving the current CRISPR technology for target identification and to accelerate the drug discovery process. Before joining the FGC, David was a Senior Scientist at Horizon Discovery implementing novel CRISPR based target identification approaches and driving target identification and validation programs. He received his PhD from the Biozentrum at the University of Basel, Switzerland and completed postdoctoral research at the Biotech Research & Innovation Centre of the University of Copenhagen, Denmark.